HRP20220536T1 - Liječenje pacijenta lijekom supstratom cyp3a4 koji je kontraindiciran za istodobnu primjenu s jakim inhibitorom cyp3a4 - Google Patents

Liječenje pacijenta lijekom supstratom cyp3a4 koji je kontraindiciran za istodobnu primjenu s jakim inhibitorom cyp3a4 Download PDF

Info

Publication number
HRP20220536T1
HRP20220536T1 HRP20220536TT HRP20220536T HRP20220536T1 HR P20220536 T1 HRP20220536 T1 HR P20220536T1 HR P20220536T T HRP20220536T T HR P20220536TT HR P20220536 T HRP20220536 T HR P20220536T HR P20220536 T1 HRP20220536 T1 HR P20220536T1
Authority
HR
Croatia
Prior art keywords
substrate drug
cyp3a4 substrate
patients
patient
cyp3a4
Prior art date
Application number
HRP20220536TT
Other languages
English (en)
Croatian (hr)
Inventor
Sundar Srinivasan
Christina Chow
Original Assignee
Bow River LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bow River LLC filed Critical Bow River LLC
Publication of HRP20220536T1 publication Critical patent/HRP20220536T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HRP20220536TT 2017-05-16 2017-05-16 Liječenje pacijenta lijekom supstratom cyp3a4 koji je kontraindiciran za istodobnu primjenu s jakim inhibitorom cyp3a4 HRP20220536T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/596,585 US10376507B2 (en) 2017-05-16 2017-05-16 Method of treating a patient with a CYP3A4 substrate drug
PCT/US2017/032924 WO2018212764A1 (en) 2017-05-16 2017-05-16 Methods of treatment
EP17897227.9A EP3426250B1 (en) 2017-05-16 2017-05-16 Treating a patient with a cyp3a4 substrate drug contraindicated for concomitant administration with a strong cyp3a4 inhibitor

Publications (1)

Publication Number Publication Date
HRP20220536T1 true HRP20220536T1 (hr) 2022-06-10

Family

ID=64269934

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220536TT HRP20220536T1 (hr) 2017-05-16 2017-05-16 Liječenje pacijenta lijekom supstratom cyp3a4 koji je kontraindiciran za istodobnu primjenu s jakim inhibitorom cyp3a4

Country Status (15)

Country Link
US (6) US10376507B2 (enExample)
EP (4) EP3426250B1 (enExample)
JP (7) JP2020520380A (enExample)
KR (3) KR20210010663A (enExample)
AU (10) AU2017414697B2 (enExample)
CA (1) CA3103793A1 (enExample)
DK (2) DK3426250T3 (enExample)
ES (2) ES2912373T3 (enExample)
FI (1) FI3716976T3 (enExample)
HR (1) HRP20220536T1 (enExample)
MX (4) MX2019013714A (enExample)
PL (1) PL3426250T3 (enExample)
SI (1) SI3426250T1 (enExample)
WO (2) WO2018212764A1 (enExample)
ZA (1) ZA202006746B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
EA202090676A1 (ru) 2017-01-27 2021-10-08 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
ES2912373T3 (es) * 2017-05-16 2022-05-25 Bow River LLC Tratamiento de un paciente con un fármaco sustrato de CYP3A4 contraindicado para la administración concomitante con un inhibidor potente de CYP3A4
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
WO2018226875A2 (en) * 2017-06-07 2018-12-13 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
IL273300B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CN109966298A (zh) * 2019-05-10 2019-07-05 辽宁大学 托伐普坦在制备降血脂药物中的应用
US20220233542A1 (en) * 2019-06-05 2022-07-28 University Of Georgia Research Foundation Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP4041922A4 (en) 2019-10-07 2023-11-01 University Hospitals Cleveland Medical Center METHOD FOR TREATING WILD-TYPE ISOCITRATE DEHYDROGENASE-1 CANCER
EP4044192A4 (en) * 2019-11-15 2022-12-07 Cardio Intelligence Inc. METHOD, PROGRAM, DEVICE AND SYSTEM FOR FACILITATING THE DETERMINATION OF THE PHARMACEUTICAL FORM AND/OR DOSAGE OF A MEDICATION
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
HRP20241574T1 (hr) * 2020-04-01 2025-01-31 Otsuka Pharmaceutical Co., Ltd. Metode za početak doziranja liječenja aripiprazolom
WO2022019920A1 (en) * 2020-07-24 2022-01-27 Verastem, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2022039421A1 (ko) * 2020-08-18 2022-02-24 재단법인대구경북과학기술원 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
KR102601028B1 (ko) 2020-08-18 2023-11-10 재단법인대구경북과학기술원 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
CN111920814B (zh) * 2020-09-04 2022-02-11 郑州大学 依匹哌唑在制备抗肿瘤药物中的应用
CN112898131B (zh) * 2020-11-05 2023-08-22 苏州凯祥生物科技有限公司 大麻二酚的提取工艺及大麻二酚或大麻提取物在制备预防或者治疗bph的药物中的应用
CN112206297B (zh) * 2020-11-16 2022-01-11 深圳市宝安区人民医院 治疗心脾两虚型失眠症的中药制剂及其制备方法
US11229644B1 (en) 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
EP4271381A4 (en) * 2020-12-31 2024-12-11 Lake O'Hara LLC METHODS OF TREATMENT OF PSYCHIATRIC DISORDERS WITH BREXPIPRAZOLE IN OBESE PATIENTS
CN112675175B (zh) * 2021-02-01 2022-11-01 天津济坤医药科技有限公司 布里格替尼在制备治疗特发性肺纤维化的药物中的应用
WO2023101441A1 (ko) * 2021-11-30 2023-06-08 에스케이케미칼 주식회사 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
WO2023141634A2 (en) * 2022-01-24 2023-07-27 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US20250302821A1 (en) * 2022-05-12 2025-10-02 St. Jude Children's Research Hospital, Inc. Synergistic antifungal composition and method
CN117045643A (zh) * 2023-09-26 2023-11-14 江苏百奥信康医药科技有限公司 一种cftr矫正剂在制备治疗乳腺增生症的药物中的应用
CN117257994B (zh) * 2023-11-21 2024-03-01 北京大学人民医院 动物模型的构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973970B2 (en) * 2000-08-09 2011-07-05 Ether Visuals Llc Preventing artifacts that may be produced when bottling PDL files converted from raster images
EP2023923A2 (en) * 2006-05-25 2009-02-18 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
US7820681B1 (en) * 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US20140221424A1 (en) * 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
JP6835733B2 (ja) 2014-11-25 2021-02-24 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製法及び使用
US10493024B2 (en) 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
KR20200108371A (ko) 2016-11-09 2020-09-17 사인패스 파마 인코포레이티드 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
ES2912373T3 (es) * 2017-05-16 2022-05-25 Bow River LLC Tratamiento de un paciente con un fármaco sustrato de CYP3A4 contraindicado para la administración concomitante con un inhibidor potente de CYP3A4

Also Published As

Publication number Publication date
KR20210045400A (ko) 2021-04-26
AU2020203606A1 (en) 2020-06-25
ES2912373T3 (es) 2022-05-25
AU2022228153A1 (en) 2022-09-29
AU2018432858A1 (en) 2021-01-07
US11123346B2 (en) 2021-09-21
US20180333411A1 (en) 2018-11-22
JP7698009B2 (ja) 2025-06-24
AU2020202266A1 (en) 2020-04-23
AU2020250281B2 (en) 2022-07-28
ES2993832T3 (en) 2025-01-10
WO2020018136A1 (en) 2020-01-23
JP2020520380A (ja) 2020-07-09
AU2020250281A1 (en) 2020-11-05
AU2022204806A1 (en) 2022-11-10
US20210154189A1 (en) 2021-05-27
KR102805232B1 (ko) 2025-05-13
JP2021510681A (ja) 2021-04-30
AU2018432858B2 (en) 2025-10-09
CA3103793A1 (en) 2020-01-23
FI3716976T3 (fi) 2024-10-25
AU2022204806B2 (en) 2025-04-24
US20180333410A1 (en) 2018-11-22
SI3426250T1 (sl) 2022-09-30
AU2017414697B2 (en) 2020-03-05
JP2023021260A (ja) 2023-02-10
JP2021059610A (ja) 2021-04-15
JP6984024B2 (ja) 2021-12-17
JP7353343B2 (ja) 2023-09-29
EP4461298A2 (en) 2024-11-13
JP2025137510A (ja) 2025-09-19
AU2020203607B2 (en) 2020-07-09
AU2020203607A1 (en) 2020-06-25
JP2023174661A (ja) 2023-12-08
US20180333409A1 (en) 2018-11-22
KR20210010663A (ko) 2021-01-27
JP2022022264A (ja) 2022-02-03
AU2020202100A1 (en) 2020-04-09
EP4461298A3 (en) 2025-01-22
EP3426250B1 (en) 2022-03-23
AU2020202266B2 (en) 2020-05-14
AU2020203606B2 (en) 2020-07-09
MX2021000609A (es) 2021-06-23
KR20200010320A (ko) 2020-01-30
MX2025000380A (es) 2025-02-10
CA3062770A1 (en) 2018-11-22
EP3716976B1 (en) 2024-08-07
US20190076425A1 (en) 2019-03-14
PL3426250T3 (pl) 2022-08-08
AU2020203608B2 (en) 2020-07-09
AU2017414697A1 (en) 2019-11-07
EP3426250A1 (en) 2019-01-16
EP3426250A4 (en) 2020-05-06
AU2020202100B2 (en) 2020-07-02
EP4082546A1 (en) 2022-11-02
MX2019013714A (es) 2020-07-14
AU2022228153B2 (en) 2025-04-24
US10835529B2 (en) 2020-11-17
MX2022013410A (es) 2022-11-14
AU2020203608A1 (en) 2020-06-25
DK3426250T3 (da) 2022-05-16
US20190255043A1 (en) 2019-08-22
EP3716976A4 (en) 2021-02-17
ZA202006746B (en) 2023-03-29
WO2018212764A1 (en) 2018-11-22
DK3716976T3 (da) 2024-10-28
US10376507B2 (en) 2019-08-13
EP3716976A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
HRP20220536T1 (hr) Liječenje pacijenta lijekom supstratom cyp3a4 koji je kontraindiciran za istodobnu primjenu s jakim inhibitorom cyp3a4
US11419860B2 (en) Methods of treatment
US12453730B2 (en) Methods of treatment